Ron Leuty

Peninsula companies to merge in potential $820M deal centered around a drug that was cast off by Novartis - San Francisco Business Times This hepatitis drug was cast off by Novartis. Now it's the center of a potential $820 million deal between two Peninsula companies.

Novartis dropped this hepatitis drug years ago. Bluejay picked it up, leading to a potential $820 buyout by Mirum Pharmaceuticals - San Francisco Business Times www.bizjournals.com/sanfrancisco...

Structure Therapeutics stock doubles after weight-loss drug shows promising results in clinical trials - San Francisco Business Times Fat-fighting biotech company soars: Investors sent Structure Therapeutics' stock flying high after the company disclosed results from two studies testing different doses of its oral GLP-1 drug.

Structure Therapeutics' stock soars on trial results of GLP-1 drug - San Francisco Business Times www.bizjournals.com/sanfrancisco...

Peninsula company rides blank check to Wall Street after raising more than $1 billion as a startup - San Francisco Business Times Freenome will go public via a SPAC merger at $1.14 billion valuation, the latest biotech to test the markets.

Cancer test company Freenome to go public in $330 million SPAC deal - San Francisco Business Times www.bizjournals.com/sanfrancisco...

Cassidy continues to pay lip service to the public health catastrophe he created with his cowardice.

How a Covid vaccine deal could fuel this South S.F. company's work against other viruses - San Francisco Business Times 'We're getting a lot of interest lately," this company's CEO said after a deal that saved the company's Covid vaccine push.

Why Vaxart leaders think its oral Covid vax deal could open the door to the rest of its vaccines - San Francisco Business Times www.bizjournals.com/sanfrancisco...

An independent pharmacy near Boston Medical Center for >3 decades has posted a GoFundMe because they're "currently experiencing financial difficulties due to reimbursement issues, which have led to bare shelves & challenges in paying staff." www.boston25news.com/news/local/b... #medsky

Peninsula project lands first new tenant more than four years after launching a conversion to biotech - San Francisco Business Times Converted for biotech, Peninsula project lands 1st life sciences tenant years later

Curve Bio is first new biotech tenant in Longfellow's conversion project, the San Mateo Science Center - San Francisco Business Times www.bizjournals.com/sanfrancisco...

Gilead Sciences is planning an 800,000 square foot expansion at its Foster City headquarters - San Francisco Business Times Buildup: Inside Gilead's plans for 800K square feet in Foster City

ICYMI: Gilead Sciences is looking at a potential 800,000-square-foot expansion at its HQ campus - San Francisco Business Times www.bizjournals.com/sanfrancisco...

A 'renter’s market' allowed this CEO to bring everyone together for less - San Francisco Business Times How this biotech company plans to bring its team together for less

How Twist Bio brought its team into one space with help of a renter's market www.bizjournals.com/sanfrancisco...

Octave Bio lands massive deal with Quest Diagnostics that will expand reach of its multiple sclerosis tests - San Francisco Business Times Octave Bio lands massive deal with Quest Diagnostics that will expand reach of its multiple sclerosis tests

Quest Diagnostics inks deal to supply Octave Bioscience's MS test - San Francisco Business Times www.bizjournals.com/sanfrancisco...

Gilead Sciences is planning an 800,000 square foot expansion at its Foster City headquarters - San Francisco Business Times Buildup: Inside Gilead's plans for 800K square feet in Foster City

Gilead Sciences targets 800,000-square-foot expansion at HQ campus - San Francisco Business Times www.bizjournals.com/sanfrancisco...

After pivot, this Bay Area CEO says company is hiring and 'almost to the starting line' - San Francisco Business Times "A drug that stops kidney function decline is transformative," Vera Therapeutics founder and CEO Marshall Fordyce said.

How this Bay Area biotech pivoted, is hiring and is 'almost to the starting line' - San Francisco Business Times www.bizjournals.com/sanfrancisco...

Berkeley and Emeryville built for biotech just before the sector crashed — what happens with those vacant buildings now? - San Francisco Business Times In a sign of trouble for the East Bay's life sciences cluster, Oxford Properties is selling its Emeryville site after abandoning lab development plans. Here's how that makes for part of the bigger pic...

Berkeley and Emeryville built for biotech just before the sector crashed — what happens with those vacant buildings now? - San Francisco Business Times www.bizjournals.com/sanfrancisco...

Abbott Laboratories and Cologuard maker Exact Sciences land $23 billion deal — Here's how Bay Area could be affected - San Francisco Business Times Why Abbott Labs is making a big buy with potential Bay Area impact

Abbott Laboratories and Cologuard maker Exact Sciences land $23 billion deal — Here's how Bay Area could be affected www.bizjournals.com/sanfrancisco...

East Bay AI biotech company raises $106 million from Jeff Bezos and others - San Francisco Business Times Created by leaders of a Salesforce skunkworks, this East Bay AI company just raised $106 million from Jeff Bezos and others.

Profluent, which just raised $106M from Jeff Bezos and others, launched a partnership with the Rett Syndrome Research Trust that focuses on base editors to permanently correct mutations to the gene that cause the rare neurodevelopment disorder www.bizjournals.com/sanfrancisco...

Freenome lands global commercialization deal with Roche for blood-based colon cancer test - San Francisco Business Times Brisbane-based Freenome has locked in a second major partnership for its blood-based cancer screening test, this time with a Switzerland-based diagnostics giant that already has invested hundreds of m...

In big win for Freenome's CEO in his 1st year, cancer test company inks deal with Roche - San Francisco Business Times www.bizjournals.com/sanfrancisco...

Former Amgen site head joins Genentech as former Genentech cancer immunology exec moves to Amgen - San Francisco Business Times Two big biotech companies have traded top research executives. Learn who went where.

Former Amgen site head joins Genentech as former Genentech cancer immunology exec moves to Amgen
www.bizjournals.com/sanfrancisco...

Sutter Health to build record-setting new hospital campus in Santa Clara - San Francisco Business Times Sutter Health has earmarked its largest ever facilities investment with a major hospital project in Santa Clara.

Sutter Health will construct a 272-bed, eight-story medical center near Levi’s Stadium as part of the not-for-profit health care system's $2.8 billion buildout in the heart of Silicon Valley.
www.bizjournals.com/sanfrancisco...

Louisiana restricts access to abortion pills by classifying them as a controlled substance A bill that would restrict access to abortion pills has been signed into law in Louisiana. The law reclassifies the drugs as a controlled substance, grouping them with Xanax and Valium. Possession wit...

Scheduling mifepristone largely invalidates the point of the schedule.

Ostensibly, the schedule is meant to monitor drugs *which have the ability to form physical dependence*.

This step makes the schedule a list of drugs that lawmakers dislike for feelings reasons.
www.pbs.org/news-hour/sh...

Jeff Bluestone to step down as CEO of Sonoma Biotherapeutics - San Francisco Business Times Biotech's co-founder won Nobel Prize. Now another is exiting CEO job

Jeff Bluestone exits as Sonoma Bio CEO as Stephen Dilly steps in - San Francisco Business Times www.bizjournals.com/sanfrancisco...

Revolution Medicine is 'within sight' of 1,000 employees and looking for a new office to fit them - San Francisco Business Times "We're growing a lot. There's more growth ahead of us," says Revolution Medicines CEO Mark Goldsmith. Here's how his company is defying the biotech sector's pain.

Revolution Medicines is doing something truly revolutionary — it's hired hundreds just this year and it's still looking for more people
www.bizjournals.com/sanfrancisco...

AbbVie and Calico end groundbreaking partnership after 11 years without an approved drug - San Francisco Business Times An 11-year, $2 billion partnership has yet to produce an approved drug, but five attempts are in clinical trials.

AbbVie and Calico end 11-year partnership without approved drug - San Francisco Business Times www.bizjournals.com/sanfrancisco...

California group joins massive suit alleging price fixing by 'mafia enforcer' for major insurers - San Francisco Business Times The nation’s largest health insurance companies stand accused of conspiring to suppress reimbursement rates for hundreds of millions of medical procedures. They call it competition. Plaintiffs say it'...

Health care providers join suit alleging 'price-fixing' by 'cartel' of insurers for out-of-network work www.bizjournals.com/sanfrancisco...

This East Bay company had an IPO less than two years ago. Now it's laying off a quarter of its staff and installing a new CEO - San Francisco Business Times Metagenomi will cut 31 jobs and shift focus to its hemophilia A gene therapy as founding CEO Brian Thomas steps down and Jian Irish takes over.

The nine-year-old company, which IPO'd in February 2024, peaked at 237 employees in spring 2024. New cuts will bring its workforce under 100. www.bizjournals.com/sanfrancisco...

The Trump-MAHA-Stanford nexus of US health policy | CNN Politics In early 2022, Stanford medical student Santiago Sanchez set out to organize a campus debate with Jay Bhattacharya — a professor at the university whose outspoken denunciations of pandemic lockdowns m...

I spoke to CNN about how demoralizing it was to watch Stanford leadership stay silent while contrarians on campus launched unscientific attacks to stifle Stanford researchers. Now, those attacks have gone nationwide and much of MAHA leadership have ties to Stanford.

www.cnn.com/2025/11/08/p...

Codexis switches CEOs as it lays off workers and grabs manufacturing space in East Bay - San Francisco Business Times Here's why a Peninsula biotech switched CEOs, cut jobs and took new space in Hayward.

"Our technology has the potential to truly enable the delivery of a breadth of siRNA therapeutic opportunities to all patient populations." www.bizjournals.com/sanfrancisco...

Step 1: Make things more expensive by taxing them

Step 2: Realize you're unpopular because of Step 1

Step 3: Use finances (illegally) obtained via taxes to buy support

Step 4: Drive up prices because you've subsidized taxed consumption

How Adverum and its pioneering gene therapy ended up in a buyout by drug giant Lilly - San Francisco Business Times Here’s exactly how Adverum and its pioneering gene therapy ended up in an unusual deal with Lilly.

Adverum warned in August of its desperate need for cash. It turns out it was already was deep in talks with Lilly at that time, but on a licensing deal, not a buyout. Then a loan. www.bizjournals.com/sanfrancisco...

Kezar Life Sciences to lay off 70% of workforce as dispute with FDA apparently continues - San Francisco Business Times Kezar Life Sciences to cut 70% of jobs in restructuring

Kezar Life Sciences to lay off 70% amid FDA setback - San Francisco Business Times www.bizjournals.com/sanfrancisco...

Denali Therapeutics is losing Carole Ho, as she heads to Lilly as head of neuroscience - San Francisco Business Times Key Denali Therapeutics exec exits to head Lilly's neuroscience unit

Denali Therapeutics' Carole Ho leaves for Lilly neuroscience job - San Francisco Business Times www.bizjournals.com/sanfrancisco...